KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer

Pretreatment evaluation of Helios+Tregs/KIR2DL2/DL3+NKs and 1-month posttreatment CD3+/ KIR2DL2/DL3+NKs will predict nivolumab response in mRCCs.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-08-21
DOI
https://doi.org/10.1158/1078-0432.ccr-24-0729
Citations
3
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.85

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer

Anna Maria Bello, Crescenzo D’Alterio, Elisabetta Coppola, Joan Carles et al.
3 citations
Clinical Cancer Research
Cancer Immunotherapy and Biomarkers
0.85
article

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer

Anna Maria Bello, Crescenzo D’Alterio, Elisabetta Coppola, Joan Carles, Caterina Ieranò, Marilena Di Napoli, Sisto Perdonà, Christophe Caux, Stefania Scala, Bertrand Dubois, Helen Boyle, Daniela Califano, Luigi Portella, Sabrina Rossetti, Paolo Chiodini, Mario Fordellone, Anna Maria Trotta, Maria Napolitano, Sara Santagata, Sandro Pignata, Giuseppina Rea, Florinda Feroce, Giuseppe Guardascione, Rosa Azzaro
article en
3 citations

Abstract

Pretreatment evaluation of Helios+Tregs/KIR2DL2/DL3+NKs and 1-month posttreatment CD3+/ KIR2DL2/DL3+NKs will predict nivolumab response in mRCCs.

Clinical Cancer ResearchVol. 30(20)
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), University of Campania "Luigi Vanvitelli" (IT), Centre Léon Bérard (FR), Centre de Recherche en Cancérologie de Lyon (FR), Vall d'Hebron Hospital Universitari (ES), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro
Good health and well-being
Openalex Percentile: Top 23%
Cancer Immunotherapy and Biomarkers
0.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.